Journal article
The influence of acute SSRI administration on white matter microstructure in patients suffering from major depressive disorder and healthy controls
- Abstract:
-
Background: Selective serotonin reuptake inhibitors (SSRIs) are predominantly prescribed for people suffering from major depressive disorder. These antidepressants exert their effects by blocking the serotonin transporter (SERT), leading to increased levels of serotonin in the synaptic cleft and subsequently to an attenuation of depressive symptoms and elevation in mood. Although long-term studies investigating white matter (WM) alterations after exposure to antidepressant treatment exist, results on the acute effects on the brain’s WM microstructure are lacking.
Methods: In this interventional longitudinal study, 81 participants were included (33 patients and 48 healthy controls). All participants underwent diffusion weighted imaging on 2 separate days, receiving either citalopram or placebo using a randomized, double-blind, cross-over design. Fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity were calculated within the FMRIB software library and analyzed using tract-based spatial statistics.
Results: The repeated-measures ANOVA model revealed significant decreases after SSRI administration in mean diffusivity, axial diffusivity, and radial diffusivity regardless of the group (P < .05, family-wise error [FWE] corrected). Results were predominantly evident in frontal WM regions comprising the anterior corona radiata, corpus callosum, and external capsule and in distinct areas of the frontal blade. No increases in diffusivity were found, and no changes in fractional anisotropy were present.
Conclusions: Our investigation provides the first evidence, to our knowledge, that fast WM microstructure adaptations within 1 hour after i.v. SSRI administration precede elevations in mood due to SSRI treatment. These results add a new facet to the complex mode of action of antidepressant therapy. This study was registered at clinicaltrials.gov with the identifier NCT02711215.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 5.1MB, Terms of use)
-
- Publisher copy:
- 10.1093/ijnp/pyab008
Authors
- Funder identifier:
- https://ror.org/03zcxha54
- Grant:
- 2014_A192
- Publisher:
- Oxford University Press
- Journal:
- International Journal of Neuropsychopharmacology More from this journal
- Volume:
- 24
- Issue:
- 7
- Pages:
- 542-550
- Publication date:
- 2021-03-01
- Acceptance date:
- 2021-02-25
- DOI:
- EISSN:
-
1469-5111
- ISSN:
-
1461-1457
- Pmid:
-
33667309
- Language:
-
English
- Keywords:
- Pubs id:
-
2118982
- Local pid:
-
pubs:2118982
- Deposit date:
-
2025-04-18
- ARK identifier:
Terms of use
- Copyright holder:
- Seiger et al.
- Copyright date:
- 2021
- Rights statement:
- © The Author(s) 2021. Published by Oxford University Press on behalf of CINP. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http:// creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
If you are the owner of this record, you can report an update to it here: Report update to this record